NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas

被引：401

作者：

Kulke, Matthew H. ^{[1
]}

Anthony, Lowell B. ^{[2
]}

Bushnell, David L. ^{[3
]}

de Herder, Wouter W. ^{[4
]}

Goldsmith, Stanley J. ^{[5
]}

Klimstra, David S. ^{[6
]}

Marx, Stephen J. ^{[7
]}

Pasieka, Janice L. ^{[8
]}

Pommier, Rodney F. ^{[9
]}

Yao, James C. ^{[10
]}

Jensen, Robert T. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Louisiana State Univ, Div Hematol Oncol, Hlth Sci Ctr, New Orleans, LA USA

[3] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA

[4] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[5] Cornell Univ, Div Nucl Med, Dept Radiol, New York Presbyterian Hosp,Weill Med Coll, Ithaca, NY 14853 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA

[7] NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA

[8] Univ Calgary, Dept Surg, Calgary, AB, Canada

[9] Oregon Hlth & Sci Univ, Div Surg Oncol, Dept Gen Surg, Portland, OR 97201 USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

[11] NIH, Digest Dis Branch, Bethesda, MD 20892 USA

来源：

PANCREAS | 2010年 / 39卷 / 06期

关键词：

islet cell; gastric; carcinoid; guidelines; review; ZOLLINGER-ELLISON-SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; SOMATOSTATIN-RECEPTOR SCINTIGRAPHY; GASTRIC CARCINOID-TUMORS; PROTON-PUMP INHIBITORS; ISLET-CELL-CARCINOMA; DUODX AFFECT RATE; PHASE-II TRIAL; LONG-TERM; LIVER METASTASES;

D O I：

10.1097/MPA.0b013e3181ebb168

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classification and management of patients with these tumor subtypes. We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies.

引用

页码：735 / 752

页数：18

共 50 条

[21] PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from Heal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma [J].

Sangoi, Ankur R. ;

Ohgami, Robert S. ;

Pai, Rish K. ;

Beck, Andrew H. ;

McKenney, Jesse K. ;

Pai, Reetesh K. .

MODERN PATHOLOGY, 2011, 24 (03) :412-424

[22] Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors [J].

Panzuto, Francesco ;

Lamarca, Angela ;

Fazio, Nicola .

CANCER TREATMENT REVIEWS, 2024, 129

[23] ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors [J].

Falconi, Massimo ;

Bartsch, Detlef Klaus ;

Eriksson, Barbro ;

Kloeppel, Guenter ;

Lopes, Jose M. ;

O'Connor, Juan M. ;

Salazar, Ramon ;

Taal, Babs G. ;

Vullierme, Marie Pierre ;

O'Toole, Dermot .

NEUROENDOCRINOLOGY, 2012, 95 (02) :120-134

[24] Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience [J].

Fine, Robert L. ;

Gulati, Anthony P. ;

Krantz, Benjamin A. ;

Moss, Rebecca A. ;

Schreibman, Stephen ;

Tsushima, Dawn A. ;

Mowatt, Kelley B. ;

Dinnen, Richard D. ;

Mao, Yuehua ;

Stevens, Peter D. ;

Schrope, Beth ;

Allendorf, John ;

Lee, James A. ;

Sherman, William H. ;

Chabot, John A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :663-670

[25] New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors [J].

Scoville, Steven D. ;

Cloyd, Jordan M. ;

Pawlik, Timothy M. .

EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (02) :183-191

[26] Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors [J].

Cheng, Yue-Juan ;

Meng, Chang-Ting ;

Ying, Hong-Yan ;

Zhou, Jian-Feng ;

Yan, Xiao-Yan ;

Gao, Xin ;

Zhou, Na ;

Bai, Chun-Mei .

MEDICINE, 2018, 97 (45)

[27] The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors [J].

Cloyd, Jordan M. ;

Konda, Bhavana ;

Shah, Manisha H. ;

Pawlik, Timothy M. .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) :101-108

[28] Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors [J].

Strosberg, Jonathan R. ;

Fisher, George A. ;

Benson, Al B. ;

Anthony, Lowell B. ;

Arslan, Bulent ;

Gibbs, John F. ;

Greeno, Edward ;

Iyer, Renuka V. ;

Kim, Michelle K. ;

Maples, William J. ;

Philip, Philip A. ;

Wolin, Edward M. ;

Cherepanov, Dasha ;

Broder, Michael S. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (08) :2450-2459

[29] Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors [J].

Walter, Thomas ;

Bruneton, Domitille ;

Cassier, Philippe A. ;

Hervieu, Valerie ;

Pilleu, Frank ;

Scoazec, Jean Yves ;

Chayvialle, Jean Alain ;

Lombard-Bohas, Catherine .

CLINICAL COLORECTAL CANCER, 2010, 9 (04) :248-254

[30] Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study [J].

Huang, Ju ;

Liu, Huimin ;

Yang, Dekun ;

Xu, Tianming ;

Wang, Jing ;

Li, Jingnan .

CHINESE MEDICAL JOURNAL, 2024, 137 (06) :720-728

← 1 2 3 4 5 →